Natera Announces Pricing of $250 Million Follow-On Offering
07 Setembro 2023 - 1:09AM
Business Wire
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA
(cfDNA) testing, today announced the pricing of its underwritten
public offering of 4,550,000 shares of its common stock at a price
to the public of $55.00 per share. Closing of the offering is
expected to occur on September 11, 2023, subject to customary
closing conditions. In addition, Natera has granted the
underwriters a 30-day option to purchase up to an additional
682,500 shares of its common stock at the public offering price
less the underwriting discounts and commissions.
Morgan Stanley, Goldman Sachs & Co. LLC, TD Cowen and Piper
Sandler are acting as joint book-running managers for the offering.
Baird is acting as lead manager for the offering. Raymond James and
Craig-Hallum are acting as co-managers for the offering.
The securities described above are being offered pursuant to an
automatically effective shelf registration statement on Form S-3
that was filed with the U.S. Securities and Exchange Commission
(the “SEC”) on September 6, 2023, including a preliminary
prospectus. Copies of the preliminary prospectus and, when
available, final prospectus may be obtained by contacting Morgan
Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick
Street, 2nd Floor, New York, NY 10014; Goldman Sachs & Co. LLC,
200 West Street, New York, NY 10282, Attention: Prospectus
Department, by telephone at (866) 471-2526 or by emailing
Prospectus-ny@ny.email.gs.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or
Piper Sandler & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800)
333-6000, or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and enable earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 150 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas and San
Carlos, California.
Forward-looking Statements
Except for historical information, certain statements in this
press release, including statements regarding the closing of the
follow-on offering, are forward-looking in nature and are subject
to risks, uncertainties and assumptions about Natera and its
business, including, without limitation, risks and uncertainties
related to satisfaction of the closing conditions related to the
follow-on offering. Such forward-looking statements involve
substantial risks and uncertainties that relate to future events
and the actual results could differ significantly from those
expressed or implied by the forward-looking statements. Any
forward-looking statements are based on Natera’s current
expectations, estimates and assumptions regarding future events and
are applicable only as of the dates of such statements. Natera
makes no commitment to revise or update any forward-looking
statements in order to reflect events or circumstances that may
change, except as required by law. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to Natera’s business in general, please refer to
the “Risk Factors” section in Natera’s automatically effective
shelf registration statement on Form S-3 filed with the SEC on
September 6, 2023, including the documents incorporated by
reference therein, including its Annual Report on Form 10-K filed
with the SEC on March 1, 2023 and its Quarterly Reports on Form
10-Q filed with the SEC on May 10, 2023 and August 4, 2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906728529/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera,
Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024